Aa
ReZoom Lens
Has anyone had any experience, positive or negative with ReZoom lens?
$213 million dollar damages award. Left off the millions.
hud-you need to diversify your investments. Just look at this board with patients. I do not find one unhappy ReZoom patient and quite a few ReStor patients. The cream will rise to the top.The most important thing is improving peoples lives and all of these lenses have the chance to do that. Your first post blasts the ReZoom. Without going into tecno jargon,there are many invalid accusations in you responses. There are many happy patients with all technologies involved. And there are many variables that go into every case. I personally feel the ReZoom is more forgiving and provides better outcomes across the board but that is only one opinion. I do not disagree with happy ReStor patients or Crystalens patients because they are happy and that is all that counts. Time and results will be the determining factor in spite of marketing and vested intertests. You can blast the Array but my father and uncle have it and love it. The recent ruling by CMS changed the playing field and now people have to pay for it instead of having it covered. The ReZoom is an improved product or second generation based on research after seven years of implantation. The ReStor is a first generation with the results yet to be determined. Throw out all the stock market stuff and look at the science. The most important thing is to improve the quality of life and help us try to see like we did 20 years ago. Different strokes for different folks. I have already placed my bet and we tend to differ, but that is okay. Competition is good and drives improvement. The bottom line is that the patient should win.
Yeah, I am a commercial for Restor. I am a happy Restor patient who uses a computer all day without glasses. I don't crochet or do crossword puzzles. I golf, play the piano, read menus in any light, read the stock charts, and I can read product inserts. It's my business to know the technical side of devices. Nestle does own the majority of Alcon stock, but so does Fidelity, Vanguard, etc, and others. Who owns AMO? The bank. This company is so heavily mortgaged, it may never make a profit. I get my info from my doctor, as well as from Jim Mazzo, Cary Rayment, Bill Link, and Liz Davila, and other principals of the various companies when they present financial outlooks for their respective companies. At the last presentation, the president of AMO was even suggesting that surgeons should mix his product with another company's product in the same patient. That tells me that even AMO doesn't have full confidence in Rezoom. Face it, they took the Array and made it more distant dominant with Rezoom - and that makes it a presbyopia-correcting IOL?
AMO had 100% marketshare of foldable IOL's until Alcon launched Acrysof. Now AMO has about 25% and has scrambled to get in the acrylic business. That's not a choice, it is survival. They also had 100% of the multifocal marketshare, until Alcon entered it. AMO will be lucky to keep 25% of the multifocal business-that's why they are urging to use it 50% of the time. Since you are on the professional side, you mark my words: Rezoom will be sold at a lower price soon. Do your patients a favor and and either get on the Restor train, or get run over by it.
AMO had 100% marketshare of foldable IOL's until Alcon launched Acrysof. Now AMO has about 25% and has scrambled to get in the acrylic business. That's not a choice, it is survival. They also had 100% of the multifocal marketshare, until Alcon entered it. AMO will be lucky to keep 25% of the multifocal business-that's why they are urging to use it 50% of the time. Since you are on the professional side, you mark my words: Rezoom will be sold at a lower price soon. Do your patients a favor and and either get on the Restor train, or get run over by it.
To Hud
Well for someone in the financial end of business you sure claim to know alot of info about the technical side of the business. It seems that you may not have done a thorough job of your research. To me, you are causing alot of confusion to people on this website who are confused enough as is and are coming here for help. Eyesight is a precious and nobody wants to come here and walk away thinking they made a mistake by not having a ReSTOR after reading your biased, unfounded opinions.
For the record, as a nurse, as someone who works on the medical/surgical side of the eye business, and who sleeps well at night knowing that I try hard to make a better difference for people everyday.....
Alcon is owed by Nestle, yes the chocolate people so they have deep pockets/lots of money and that means tons of marketing. Everyone is the business world knows that marketing the same message over and over is successful even if it is not truthful.
True Alcon does not sell silicone lenses, AMO sells both silicone and acrylic, each has it's place. Imagine that, a comany that offers choices for it's customers! It is not the Alcon Acrysof square edge that lowers PCO (posterior capsule opacification -or wax paper like membrane after a period of time after cataract surgery) It is the square edge. This has nothing to do with the material but the design. AMO has it the square posterior edge on both silicone and acrylic lenses. The Array did not have the square edge, the ReZoom does. The Array was designed before the science was done to proof that the square edge lowers PCO. You are incorrect again with your comments about the difference in Array and ReZoom. There are 5 rings and 3 of the 5 are changed, not one. It is not called Array 2. The only people htat call ReZoom Array2 are Alcon people. There was an Array 2 briefly in Europe but not in the US. A 3 piece lens is ideal because there may be a compromise during any given surgery whereby the surgeon needs to put the lens in the sulcus instead of the bag. You absolutely cannot and should not do this with the one piece and definitely not the ReSTOR. Interestingly enough, Alcon now has the ReSTOR available on the 3 piece as well as the one piece. Again, imagine that. As for the harmful blue light, where is the science there? And what does that do to contrast sensitivity especially on a diffractive optic where contrast is already an issue? As for the Tecnis Multifocal, it is doing very well in Europe competing with ReSTOR. All of the new lenses Crystalens, ReSTOR, and ReZoom have their sweet spot. I hope that all of the people on this website coming for answers back me up and see you are trying to push ReSTOR and bash ReZoom. Shame on you.
Well for someone in the financial end of business you sure claim to know alot of info about the technical side of the business. It seems that you may not have done a thorough job of your research. To me, you are causing alot of confusion to people on this website who are confused enough as is and are coming here for help. Eyesight is a precious and nobody wants to come here and walk away thinking they made a mistake by not having a ReSTOR after reading your biased, unfounded opinions.
For the record, as a nurse, as someone who works on the medical/surgical side of the eye business, and who sleeps well at night knowing that I try hard to make a better difference for people everyday.....
Alcon is owed by Nestle, yes the chocolate people so they have deep pockets/lots of money and that means tons of marketing. Everyone is the business world knows that marketing the same message over and over is successful even if it is not truthful.
True Alcon does not sell silicone lenses, AMO sells both silicone and acrylic, each has it's place. Imagine that, a comany that offers choices for it's customers! It is not the Alcon Acrysof square edge that lowers PCO (posterior capsule opacification -or wax paper like membrane after a period of time after cataract surgery) It is the square edge. This has nothing to do with the material but the design. AMO has it the square posterior edge on both silicone and acrylic lenses. The Array did not have the square edge, the ReZoom does. The Array was designed before the science was done to proof that the square edge lowers PCO. You are incorrect again with your comments about the difference in Array and ReZoom. There are 5 rings and 3 of the 5 are changed, not one. It is not called Array 2. The only people htat call ReZoom Array2 are Alcon people. There was an Array 2 briefly in Europe but not in the US. A 3 piece lens is ideal because there may be a compromise during any given surgery whereby the surgeon needs to put the lens in the sulcus instead of the bag. You absolutely cannot and should not do this with the one piece and definitely not the ReSTOR. Interestingly enough, Alcon now has the ReSTOR available on the 3 piece as well as the one piece. Again, imagine that. As for the harmful blue light, where is the science there? And what does that do to contrast sensitivity especially on a diffractive optic where contrast is already an issue? As for the Tecnis Multifocal, it is doing very well in Europe competing with ReSTOR. All of the new lenses Crystalens, ReSTOR, and ReZoom have their sweet spot. I hope that all of the people on this website coming for answers back me up and see you are trying to push ReSTOR and bash ReZoom. Shame on you.
Ok, I'll jump in here again. I'm in the investment business with an emphasis on medical devices. Generally speaking, anyone with a cataract will be pleased with their results, even if their replacement implant is a monofocal. Get rid of the cataract, replace it with a distance focus lens. Alcon has been the market leader in intraocular units sold in the US and the world (2 to 1)for years because of the AcrySof one-piece acrylic design has been clinically preferred by most surgeons. They have never sold a silicone IOL, and the acrysof lens has always had a square edge, and the lowest opacity rates in the industry. What does that have to do with multi-focals?
About 15 years ago, Alcon bought the IOL division of 3M for the ReSTOR diffractive lens technology.
Alcon added an apodized (reduced step heights and widths) the diffractive center on the most popular implant platform in the world to create the ReSTOR lens. They then sold the rights to diffractive technology.
What about ReZoom? Well, you have to look at Array first. AMO used data from the Array, a silicone 5 zone multifocal, and combined it with the data for their very first acrylic lens, Sensar, to gain easy approval from the FDA without doing clinical trials. The FDA submission shows the only difference between Array and Array2(now known as Rezoom)is that they enlarged one distance ring and put it on an acrylic optic. The $150 Array is now discontinued and Array2 (rezoom) is now availble to hospitals for $895. They added a square edge to be more like the leader, AcrySof.
So with Rezoom, you have a 3-piece contraption more distant-dominant than it's predecessor, filters only UV light, and has a name similar to the market leader. Sounds only slightly better than a monofocal IOL.
ReSTOR is an elegant one-piece design built on the cadillac of IOL's, and filters both UV and harmful blue light. The "lifestyle" considerations are AMO's desperate attempt to get a piece of the pie that they lost. They are also hoping to compete more effectively in 2007 when their Tecnis diffractive IOL comes to market(see who keeps copying who?). It should be better than Rezoom, but not better than Restor, because it is not apodized, and it will have glaring rings all the way out on the optic. That's what Alcon avoided in the 3M design for the last 15 years. The bottom line is the sweet spot for patient satisfaction is greater with ReSTOR, by far.
About 15 years ago, Alcon bought the IOL division of 3M for the ReSTOR diffractive lens technology.
Alcon added an apodized (reduced step heights and widths) the diffractive center on the most popular implant platform in the world to create the ReSTOR lens. They then sold the rights to diffractive technology.
What about ReZoom? Well, you have to look at Array first. AMO used data from the Array, a silicone 5 zone multifocal, and combined it with the data for their very first acrylic lens, Sensar, to gain easy approval from the FDA without doing clinical trials. The FDA submission shows the only difference between Array and Array2(now known as Rezoom)is that they enlarged one distance ring and put it on an acrylic optic. The $150 Array is now discontinued and Array2 (rezoom) is now availble to hospitals for $895. They added a square edge to be more like the leader, AcrySof.
So with Rezoom, you have a 3-piece contraption more distant-dominant than it's predecessor, filters only UV light, and has a name similar to the market leader. Sounds only slightly better than a monofocal IOL.
ReSTOR is an elegant one-piece design built on the cadillac of IOL's, and filters both UV and harmful blue light. The "lifestyle" considerations are AMO's desperate attempt to get a piece of the pie that they lost. They are also hoping to compete more effectively in 2007 when their Tecnis diffractive IOL comes to market(see who keeps copying who?). It should be better than Rezoom, but not better than Restor, because it is not apodized, and it will have glaring rings all the way out on the optic. That's what Alcon avoided in the 3M design for the last 15 years. The bottom line is the sweet spot for patient satisfaction is greater with ReSTOR, by far.
To USAF JAG ---
I strongly agree with eyecu becuase it is very important to have your old records/chart from before and immediately after LASIK. These numbers are crucial to select the correct implant power when you do have your surgery. Your surgeon already has your chart and knows your eyes. Sounds like he knows his stuff. Best of Luck!
I strongly agree with eyecu becuase it is very important to have your old records/chart from before and immediately after LASIK. These numbers are crucial to select the correct implant power when you do have your surgery. Your surgeon already has your chart and knows your eyes. Sounds like he knows his stuff. Best of Luck!
You are reading content posted in the Eye Care Archive Forum
Find out how beta-blocker eye drops show promising results for acute migraine relief.
Eye whitening, iris color change, and eyeball "bling." Eye expert Dr. John Hagan warns of the dangers from these unnecessary surgeries.
Eye expert John Hagan, MD, FACS, FAAO discusses factors to consider and discuss with your eye care team before embarking on cataract surgery.
Is treating glaucoma with marijuana all hype, or can hemp actually help?
Protect against the leading cause of blindness in older adults
Got dry eyes? Eye drops aren't the only option! Ophthalmologist John C. Hagan III, MD explains other possible treatments.
